Bernd Hirsch - Evotec AG Insider

Evotec AG -- USA Stock  

USD 26.47  0.00  0.00%

Member of the Supervisory Board

Mr. Bernd Hirsch is Vice Chairman of the Supervisory Board at Evotec AG since June 9, 2015. Previously he was Member of the Supervisory Board at Evotec AG from June 2014. He is Chairman of the Audit Committee and Member of the Remuneration and Nomination Committee at the Company. He completed his degree in business administration at JuliusMaximiliansUniversitaet Wuerzburg and afterwards gained experience in various positions in the financial area. From 1998 to 2001, he was Audit Manager at the audit firm Arthur Andersen. In 2001, he started at Carl Zeiss Group as Head of Mergers Acquisitions. One year later, Mr. Hirsch was appointed Chief Financial Officer and Member of the Executive Board at Carl Zeiss Meditec AG. From December 2009 to December 2015, he was Chief Financial Officer and member of the Executive Board of Symrise AG. From April 1, 2016 onwards, Mr. Hirsch was Chief Financial Officer of Bertelsmann SE Co. KGaA. Furthermore, he acts as Director of Bertelsmann Inc., Penguin Random House LLC, Penguin Random House Limited and RTL Group S.A. Apart from his role as member of the Supervisory Board of Evotec AG, he does not hold memberships in any other comparable supervisory bodies.
Age: 46  Executive Since 2015      
49 4056 0810

Management Efficiency

The company has return on total asset (ROA) of 5.91 % which means that it generated profit of $5.91 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.68 % meaning that it generated $13.68 on every $100 dollars invested by stockholders.
The company has accumulated 9.53 M in total debt with debt to equity ratio (D/E) of 2.5 implying the company greatly relies on financing operations through barroing. Evotec AG has Current Ratio of 4.88 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives


Loeki PutraPT Chandra Asri Petrochemical T
Pier SigismondiUnilever N V
Keith WeedUnilever N V
Jason YettonWestpac Banking Corporation
Dave BComWestpac Banking Corporation
Chaovalit EkabutPT Chandra Asri Petrochemical T
Tim HartinWestpac Banking Corporation
Takashi AmejimaNippon Telegraph and Telephone
Ritva SotamaaUnilever N V
Harry TaminPT Chandra Asri Petrochemical T
Rebecca LimWestpac Banking Corporation
Tonia LovellUnilever N V
Gary ThursbyWestpac Banking Corporation
Alexandra HolcombWestpac Banking Corporation
Andrew BowdenWestpac Banking Corporation
Christine ParkerWestpac Banking Corporation
Hon HoPT Chandra Asri Petrochemical T
Douglas BaillieUnilever N V
David LindbergWestpac Banking Corporation
Loeki PuteraPT Chandra Asri Petrochemical T
David BlanchardUnilever N V

Entity Summary

Evotec AG offer drug discovery solutions to the pharmaceutical, biotechnology, and academic sectors worldwide. Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Hamburg, and employs 1,000 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Evotec AG to your portfolio

Top Management

Evotec AG Leadership Team
Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance

Evotec AG Performance Indicators